Royalty Pharma plc Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Royalty Pharma plc (RPRX) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 147.00 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2026-08-05
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2026-06-30 was 147.00K shares, a 206.25% increase year-over-year.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2026-03-31 was 358.00K shares, a 40.33% decline year-over-year.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2025-09-30 was 79.00K shares.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2025-06-30 was 48.00K shares.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2025 was 270.00K shares.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2024 was 0.00 shares.
- Royalty Pharma plc incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 6 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 147.00K shares 10-Q · filed 2026-08-05 | 223.00K shares 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | 358.00K shares 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | 270.00K shares 10-K · filed 2026-02-11 | |||||||
| 2025-09-30 | 79.00K shares 10-Q · filed 2025-11-05 | 240.00K shares 10-Q · filed 2025-11-05 | ||||||
| 2025-06-30 | 48.00K shares 10-Q · filed 2026-08-05 | 323.00K shares 10-Q · filed 2026-08-05 | ||||||
| 2025-03-31 | 600.00K shares 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-11 | 145.91M shares 10-K · filed 2025-02-12 | ||||||
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-05 | 145.09M shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2025-11-05 | 146.58M shares 10-Q · filed 2024-11-06 | ||||
| 2024-06-30 | 0.00 shares 10-Q · filed 2025-08-06 | 145.85M shares 10-Q · filed 2024-08-08 | 0.00 shares 10-Q · filed 2025-08-06 | 147.33M shares 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 148.81M shares 10-Q · filed 2024-05-09 | ||||||
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-11 | 155.29M shares 10-K · filed 2024-02-15 | ||||||
| 2023-09-30 | 152.69M shares 10-Q · filed 2024-11-06 | 156.54M shares 10-Q · filed 2024-11-06 | ||||||
| 2023-06-30 | 155.42M shares 10-Q · filed 2024-08-08 | 158.50M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 161.61M shares 10-Q · filed 2024-05-09 | |||||||
| 2022-09-30 | 167.93M shares 10-Q · filed 2023-11-08 | 170.65M shares 10-Q · filed 2023-11-08 | ||||||
| 2022-06-30 | 170.86M shares 10-Q · filed 2023-08-08 | 172.03M shares 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | 173.22M shares 10-Q · filed 2023-05-09 | |||||||
| 2021-09-30 | 178.94M shares 10-Q · filed 2022-11-08 | 197.88M shares 10-Q · filed 2022-11-08 | ||||||
| 2021-06-30 | 197.77M shares 10-Q · filed 2022-08-04 | 207.51M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 217.35M shares 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |